Introduction {#sec1_1}
============

Currently, there are 4 types of pharmacological treatments for Alzheimer\'s disease (AD) available in Japan, namely the acetylcholinesterase inhibitors (AchEIs) donepezil, rivastigmine, and galantamine, and the NMDA receptor antagonist memantine. AchEIs are the standard treatment for patients with mild-to-moderate AD \[[@B1],[@B2]\].

AchEIs each work via characteristic mechanisms \[[@B3],[@B4],[@B5],[@B6],[@B7]\]. From reports of various meta-analyses on the efficacy of individual AchEIs, it is generally accepted that AChEIs have significant favorable effects on cognition \[[@B8],[@B9],[@B10]\]. On the other hand, one open-label randomized study reported a statistically significant improvement in behavioral and psychological symptoms of dementia (BPSD) in patients treated with memantine, donepezil, and rivastigmine, but not in those treated with galantamine \[[@B11]\]. Therefore, whether the various AchEIs exert differential effects on AD patients remains largely unknown.

Functional neuroimaging methods, such as positron emission tomography and single-photon emission computed tomography (SPECT), are widely used in the diagnosis and understanding of the pathophysiology of patients with AD. Past studies have shown changes in the regional cerebral blood flow (rCBF) and regional cerebral glucose metabolism (rCBMglc) of patients with AD receiving AchEI therapy \[[@B12],[@B13],[@B14],[@B15],[@B16],[@B17],[@B18],[@B19]\]. Most studies showed that AchEI therapy in patients with AD is associated with rCBF and rCBMglc changes, mainly in the frontal lobe. However, there was little difference in the effects of each AChEI on rCBF and rCBMglc.

The present study aimed to evaluate the differences in treatment outcomes and rCBF changes among the 3 types of AchEIs. To our knowledge, this is the first study in Japan to evaluate the differences in the effects of 3 types of AchEIs on AD patients.

In an attempt to address the question about the differential effects of AchEIs on AD patients, a randomized, 3-arm, parallel-group, 12-month clinical trial was designed to evaluate the effects of 3 AchEIs (donepezil, rivastigmine, and galantamine) that are currently available for the symptomatic treatment of AD.

Materials and Methods {#sec1_2}
=====================

Patients {#sec2_1}
--------

Patients were eligible to enter the trial if they met all of the following criteria at baseline. The diagnosis of AD was based on the NINCDS-ADRDA criteria \[[@B20]\]. All patients had Mini-Mental State Examination (MMSE) scores \[[@B21]\] of 10-24 at baseline and a dementia severity of 1 (mild) or 2 (moderate) based on the Clinical Dementia Rating \[[@B22]\]. Patients were excluded if they had the following: evidence of other neurologic or psychiatric disorders (i.e., stroke, Parkinson\'s disease, or depression); any medication with central nervous system activity; coexisting severe medical conditions or terminal diseases that would compromise the patient\'s ability to safely complete the trial, and abnormal results of biochemical analysis that may affect cognition (i.e., vitamin B~12~ deficiency, hypothyroidism, hyperammonemia, etc.).

None of the patients had the following: concomitant treatment with cholinomimetics, tricyclic antidepressants, or neuroleptics; concomitant treatment with any other psychotropic medication at the time of the first visit and during the study; evidence of bradyarrhythmia in the baseline electrocardiogram, and a history of alcohol abuse. The patients were permitted to continue receiving a fixed dose of other medications classified as antihypertensives, anticoagulants, antiplatelets, diuretics, lipid-reducing agents, and antidiabetic drugs. They underwent neuropsychological battery testing at baseline, and after 6 and 12 months of treatment, and SPECT at baseline and after 12 months of treatment.

Study Design {#sec2_2}
------------

This was a prospective, longitudinal, randomized, open-label, 3-arm, parallel-group, 12-month clinical trial comparing donepezil, rivastigmine, and galantamine.

We recruited 75 first-visit outpatients with AD, who fulfilled the conditions described in the Patients section above, from the Memory Disorder Clinic at the Department of Geriatric Medicine, Tokyo Medical University. For treatment-group allocation, we prepared 25 sheets of paper (12 sheets for men, 13 sheets for women) with the name of each of the 3 AchEIs and put them in an envelope. The patients were asked to choose one of these envelopes. Patients were hence randomized to receive treatment with 1 of the 3 AchEIs for 12 months. The dosages of all AchEIs in this study were set to those approved for mild-to-moderate AD by the Ministry of Health, Labour and Welfare of Japan. Oral donepezil was administered at a dose of 5 mg per day, transdermal rivastigmine at 18 mg per day, and oral galantamine at 24 mg per day. According to the results of a pivotal clinical trial, donepezil has been judged to be effective for mild-to-moderate AD at a dosage of 5 mg per day in Japan \[[@B23]\]. We assessed adverse events by medical examination, laboratory tests, and electrocardiogram 30 days after the start of AChEI treatment. Twenty-eight similarly aged healthy control subjects (12 men and 16 women), ranging from 51 to 85 years old (mean age 74.3 ± 8.5 years), were also included for the SPECT analysis.

This study was approved by the Ethics Committee of Tokyo Medical University. Informed consent for the SPECT studies was obtained from all control subjects. For the patients, consent was obtained before entry, following a detailed explanation of the study\'s aim. It was obtained from either the patients themselves or their closest relative. All procedures were in accordance with ethical standards on human investigation and with the principles of the declaration of Helsinki.

Assessment {#sec2_3}
----------

Treatment effects were evaluated at baseline, and after 6 and 12 months of treatment using the following 5 multidimensional rating scales: MMSE \[[@B21]\], Alzheimer\'s Disease Assessment Scale-Cognitive Subscale (ADAS-cog) \[[@B24]\], Trail Making Test (TMT)-Part A \[[@B25]\], Neuropsychiatric Inventory (NPI) \[[@B26]\], and Functional Activities Questionnaire (FAQ) \[[@B27]\]. MMSE and ADAS-cog were regarded as evaluating cognitive function. Furthermore, among the subitems of the ADAS-cog, we regarded items 1, 9, 10, and 11 as measures of memory, items 2, 3, 4, 5, and 6 as measures of language, and 7 and 8 as measures of praxis. TMT-Part A was regarded as assessment of the frontal lobe function, and NPI and FAQ were regarded as BPSD assessment by the caregiver. Assessments were performed by an experienced clinical psychologist who was blind to the patients\' clinical data.

SPECT Imaging {#sec2_4}
-------------

All subjects were imaged using a triple-head rotating gamma camera (PRISM 3000 XP, Picker) with a fan-beam collimator that permits a spatial resolution of 6.8-mm full width at half maximum. Imaging was started 15 min after intravenous injection with 222 MBq of N-isopropyl-*p*-\[^123^I\]iodoamphetamine. In practice, full width at half maximum would be higher (approximately 10-12 mm) when scanning subjects because of the increase in source to collimator distances together with the effects of scattering within subjects, both of which degrade spatial resolution. Prior to the injection, the subjects sat in quiet and relaxed surroundings with their eyes open for 10 min. After the injection, the subjects lay down with their eyes closed during the imaging. SPECT images were acquired in 24 steps (72 projections), each of which collected counts for 40 s. Reconstruction of the images was performed by filtered back-projection using Butterworth and Ramp filters (order 8; cutoff 0.40/cm) with attenuation correction (Chang method, 0.09/cm). The matrix size and slice thickness of the SPECT images were 128 × 128 mm and 4.3 mm, respectively.

3-Dimensional Stereotactic Surface Projection Analysis {#sec2_5}
------------------------------------------------------

A 3-dimensional stereotactic surface projection (3D-SSP) created with the Neurological Statistical Image Analysis Software (NEUROSTAT), developed by Minoshima et al. \[[@B28]\], was used to evaluate the spatial distribution of abnormal CBF. Image analysis was performed on a personal computer equipped with the Windows 2000 operating system, in which the MS-DOS version of NEUROSTAT was implemented. Each image set was realigned to the bicommissure stereotactic coordinate system \[[@B29]\]. Differences in individual brain sizes were adjusted by linear scaling, and regional anatomical differences were minimized by a nonlinear warping technique \[[@B30]\]. As a result, each brain was standardized anatomically to match a standard atlas brain while preserving regional perfusion activity. Subsequently, maximum cortical activity was extracted to adjacent predefined surface pixels on a pixel-by-pixel basis using the 3D-SSP technique \[[@B28]\]. To quantify perfusion changes, the normalized brain activity of each patient was compared with that of 28 normal controls using pixel-by-pixel Z-score analysis (normal mean -- individual value/normal SD). Thus, the 3D-SSP technique can transform a SPECT image of a subject to Talairach coordinates (anatomical standardization), and the regions of the 3D-SSP Z-score image correctly correspond to the Talairach coordinates \[[@B28],[@B29]\]. A positive Z-score represented an increase in rCBF, and a negative Z-score represented a decrease in rCBF in the patient relative to the mean of the controls.

Image Analysis {#sec2_6}
--------------

To demonstrate regional changes in rCBF, differences between the baseline and the endpoint were compared in each group using the paired t test. For this comparison, we used a threshold of changes in Z-score ≥1.64 (corresponding to a p value ≤0.05). Moreover, we identified regions of Talairach coordinates with changes in Z-scores ≥3 (corresponding to a p value \<0.005) \[[@B28],[@B29]\].

Statistical Analysis {#sec2_7}
--------------------

Values are expressed as means  ±  SD. Comparisons among the 3 groups were performed by one-way analysis of variance and changes of multidimensional rating scales in each group were analyzed by the paired t test. A p value \<0.05 was considered to indicate a statistically significant difference between the 2 groups.

Results {#sec1_3}
=======

Seventy-five patients (32 men and 43 women between 72 and 87 years old; mean age 74.3 ± 4.2 years) were randomly assigned to receive 1 of the 3 treatments. Figure [1](#F1){ref-type="fig"} shows the study design. Twenty-five patients were allocated to each group, namely, the donepezil group (mean dosage: 5 mg per day), the rivastigmine group (mean dosage: 18 mg per day), and the galantamine group (mean dosage: 24 mg per day). All patients received at least 1 dose of the assigned treatment and had at least 1 valid postbaseline assessment using the neuropsychological battery. In total, 55 patients (73.3%) completed the study according to the protocol. A total of 20 patients (26.7%) withdrew from the study, of whom 5 (6.6%) discontinued treatment owing to side effects as shown in figure [1](#F1){ref-type="fig"}. There was no significant difference in the frequency of side effects among the 3 groups. Adverse events were reported in 28.0% of the patients (7/25) in the donepezil group, in 28.0% (7/25) of the patients in the rivastigmine group, and in 24.0% (6/25) of the patients in the galantamine group. Table [1](#T1){ref-type="table"} shows the adverse events reported in the 3 groups. Nausea and vomiting were the most common adverse events, followed by headache and dizziness. Most adverse events in all the groups were transient, of mild-to-moderate severity, and resolved spontaneously with no need for intervention. There were no clinically significant changes from baseline in the clinical laboratory parameters and in the vital signs of all 3 groups.

Table [2](#T2){ref-type="table"} shows the demographic features of the patients. No significant differences in the 3 groups were found in terms of age, sex, length of education, duration of disease, and duration of treatment.

Table [3](#T3){ref-type="table"} shows the results of the 5 multidimensional rating scales in the 3 treatment groups. No significant differences in the 3 groups were observed in the 5 multidimensional rating scale scores at baseline, and after 6 and 12 months. After 6 months of treatment, the results of MMSE and TMT-Part A showed an improvement versus baseline in the donepezil treatment group (MMSE: p \< 0.01; TMT-Part A: p \< 0.05). At 12 months after treatment, no significant changes were observed except that the FAQ score in the galantamine group was significantly worse compared with that at the baseline (p \< 0.01). Figure [2](#F2){ref-type="fig"} shows the changes in the 5 multidimensional rating scale scores.

Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"} show the results of each assessment category of ADAS-cog (described above) and of the individual domains of the NPI in the 3 treatment groups. Regarding the assessment categories of ADAS-cog, praxis was significantly improved in the rivastigmine group at 12 months (p \< 0.01) (table [3](#T3){ref-type="table"}). The analysis of the results in the individual domains of the NPI showed that at 12 months, agitation/aggression was significantly worse in the galantamine group (p \< 0.01), whereas aberrant motor behavior was significantly improved in the galantamine group (p \< 0.05) (table [5](#T5){ref-type="table"}).

Figure [3](#F3){ref-type="fig"} shows the 3-dimensional images of significant rCBF changes from baseline at the endpoint in each of the groups. The red scale indicates relative increases in rCBF and the blue scale indicates relative decreases in rCBF. All groups showed a significant increase in rCBF in the frontal lobe. Specifically, the donepezil group showed an rCBF increase in the frontal pole and orbital surface. The rivastigmine group showed an rCBF increase in the lateral and medial frontal lobe as well as the cingulate and occipital lobe. The galantamine group showed an rCBF increase in the frontal lobe and the occipital lobe. Particularly, the 3-dimensional images showed that the rivastigmine and galantamine groups had an extensive and intense rCBF increase in the frontal lobe and the occipital lobe. Significant decreases in rCBF in the 3 groups were observed in the temporal lobe and the cingulate gyrus. In particular, there was a tendency for significant rCBF reduction in the medial temporal lobe in the donepezil group and in the cingulate in the galantamine group. Regarding the cerebellum, a similar increase or decrease in rCBF was observed in all groups.

Table [6](#T6){ref-type="table"} shows the regions of relative perfusion changes in the 3 treatment groups (Z-score changes ≥3).

Discussion {#sec1_4}
==========

The most important purpose of treatment in AD patients is to improve (or maintain) the cognitive level and BPSD. Thus, AchEIs are effective therapies for these symptoms.

The AchEIs work via various characteristic mechanisms. Donepezil is a strong AchEI with a strong inhibitory effect that is about 122 times higher against butyrylcholinesterase (BuChE) than against AchE \[[@B3]\]. On the other hand, rivastigmine is thought to act via inhibition of both AchE and BuChE \[[@B4]\]. Galantamine is an AchEI that is thought to modulate multiple subtypes of nicotinic acetylcholine receptors \[[@B7]\].

To our knowledge, this is the first prospective open-label long-term study that evaluated treatment outcomes and rCBF changes of all 3 types of AchEIs at the same time. We found 2 main results in this study. First, all AchEIs prevented the progression of cognitive impairment after 12 months of treatment, as shown by no significant decreases compared with baseline in MMSE and ADAS-cog total scores. Second, a greater relative rCBF increase in the frontal lobe was found in all AchEI treatment groups of AD patients.

From the results of previous meta-analysis studies \[[@B8],[@B9],[@B10]\], it is generally accepted that AChEIs have significant effects on cognition. The results of our study showing that progression of cognitive impairment is prevented after 12 months of treatment with any of the AchEIs are consistent with these previous studies. In one previous study, an adjusted indirect comparison showed that both donepezil and rivastigmine performed significantly better than galantamine in global cognitive assessment \[[@B8]\]. This was consistent with our results, showing statistically significant improvements in MMSE and TMT-Part A scores after 6 months of donepezil treatment and a statistically significant improvement in praxis evaluated by ADAS-cog after 12 months of rivastigmine therapy.

The results of individual direct comparison studies \[[@B31],[@B32],[@B33],[@B34]\] have been highly variable. In 2 studies comparing donepezil and galantamine, one found no significant differences in their efficacy \[[@B31]\], whereas the other one found significantly better outcomes for donepezil \[[@B32]\]. On the other hand, in the 2 studies comparing donepezil and rivastigmine \[[@B33],[@B34]\], both found the drugs to be similar with regard to cognitive outcomes, whereas the double-blinded study reported small but statistically significant differences in function favoring rivastigmine compared with donepezil \[[@B34]\]. Differences in the results of these studies and our study may be due to differences in the duration of the individual studies (our study: 48 weeks; Wilcock et al. \[[@B31]\]: 52 weeks; Jones et al. \[[@B32]\]: 12 weeks; Wilkinson et al. \[[@B33]\]: 12 weeks, and Bullock et al. \[[@B34]\]: 96 weeks).

Regarding BPSD, Hansen et al. \[[@B8]\] showed that donepezil treatment resulted in significantly improved behaviors in AD patients compared to galantamine treatment in an adjusted indirect comparison study. One randomized, open-label study comparing the effect of 3 AchEIs and memantine on BPSD showed that the improvement in BPSD is statistically significant in all groups except the galantamine group \[[@B11]\]. The results of these studies were consistent with our results showing that galantamine treatment resulted in a significantly worse FAQ score (p  \<  0.05) and agitation/aggression of NPI (p \< 0.01) at 12 months. In contrast, past studies hypothesized that allosteric potentiation at nicotinic receptors by galantamine, which enhances the release of noradrenaline, may result in improvements in BPSD \[[@B35],[@B36]\]. However, our results suggest that not only noradrenergic fibers but also various other factors (e.g. premorbid character) may influence changes in character including agitation.

The results of past SPECT and positron emission tomography studies, showing that treatment with AchEIs can improve rCBF and rCBMglc in areas of the brain associated with attention as well as mainly the frontal lobe \[[@B12],[@B13],[@B14],[@B15],[@B16],[@B17],[@B18],[@B19]\], are consistent with the results of this study. This result suggested that the frontal cortex might be easily affected by AchEIs, because the cholinergic axon to this region was relatively short. Regarding an rCBF decrease, all groups showed a decrease mainly in the temporal lobe and cingulate. In our study, there was little difference in the effect of individual AchEIs on rCBF changes.

The 3D-SSP results showed a small increase in rCBF in the donepezil group. However, the area of the brain showing a significant rCBF increase (Z-score changes ≥ 3), which was mainly in the frontal lobe, was relatively large. Thus, this might be caused by the strong effect of donepezil resulting in AchE inhibition. Therefore, donepezil may increase rCBF mainly in the frontal lobe. Moreover, the 3D-SSP results showed a large rCBF decrease in the donepezil group. However, cognitive improvement was found after 6 months of treatment in the donepezil group. We hypothesized 2 possibilities regarding this discrepancy. First, donepezil has a strong inhibitory effect on AchE. Therefore, cognitive improvement was observed regardless of rCBF decreases in regions of the frontal lobe. Second, rCBF was assessed after 12 months of treatment although cognitive improvement was found after 6 months of treatment. On the other hand, an increase in rCBF was found in the thalamus in the rivastigmine group. Rivastigmine is a dual inhibitor of AchE and BuchE. Both AchE and BuchE can regulate the activity of acetylcholine in the human brain \[[@B5],[@B6]\]. Many of the thalamic nuclei that are affected in several diseases of the nervous system have a substantial number of neurons that express BuchE \[[@B37]\].

Because galantamine is a relatively weak AchEI but has additional allosteric potentiating effects at the nicotinic receptor, it affects not only cholinergic transmission but also other neurotransmitter systems. Moreover, modulation of neurotransmitter release induced by galantamine was found not only in the frontal lobe but also in regions throughout the whole brain \[[@B38]\]. This allosteric potentiation contributes to neuronal protection against several neurotoxic stimuli \[[@B7]\]. This mechanism of galantamine can explain the results of our study. The result that the galantamine group showed no significant improvement in cognition can be explained by the fact that galantamine is a weak AchEI. The results that increases in rCBF were found in several regions other than the frontal lobe can be explained by the fact that galantamine affects neurotransmitters other than acetylcholine throughout the brain. Moreover, there is a tendency of a small rCBF decrease in the galantamine group. Considering these results, we hypothesized that galantamine may have neuroprotective effects in addition to AchE inhibition.

The results of adverse events in our study were consistent with those of previous clinical trials and meta-analyses \[[@B7]\]. The most common adverse event of patients was nausea (8%). No important changes in laboratory test values or vital signs were observed.

This study has several critical limitations. First, it was carried out in a single memory disorder clinic; therefore, the number of patients enrolled in each treatment group was relatively small. However, this was a prospective, longitudinal, randomized study of patients. Moreover, it is apparently the first study to evaluate the differences in the effects of treatment with 3 types of AchEIs on rCBF changes. Therefore, although the number of patients was small, we believe that our study is of significance. Furthermore, although assessments were made in a blind manner from the clinical data, this study was conducted according to an open-label design. Therefore, potential biases in treatment allocation cannot be excluded. In addition, this study did not include an untreated control group that would have allowed us to better quantify the extent of the improvements observed with the treatments under study. Therefore, we could not compare the effects of cognition and rCBF changes in each treatment group with an untreated control group. Finally, a potential weakness is the reliance on clinical rather than neuropathological diagnoses. We rigorously applied standardized sets of diagnostic criteria, all of which have a diagnostic accuracy of above 80% when judged according to the postmortem diagnosis. Further studies with a larger number of patients and with consideration of the results of pathologic examination are required to confirm our results. Nevertheless, the limitations inherent in this community-based study do not marginalize the importance of the information collected from the patients. This type of study is important because it enables us to obtain data in a clinical setting without experimental intervention.

In conclusion, consistent with the results of previous studies, this study found that long-term AchEI treatment prevents the progression of cognitive impairment in patients with AD. A greater relative rCBF increase in the frontal lobe was found in all AchEI treatment groups. Moreover, the results of the neuropsychiatric battery and SPECT study suggest that there is little difference between the effects of each AchEI. Therefore, these results suggest the possibility of selectively using individual AchEIs according to the characteristics of the AD patients.

This study was financially supported by research funding in part by Eisai Co., Ltd., Novartis Pharma K.K., Takeda Chemicalk Industries, Ltd., Janssen Pharmaceutical K.K., and Daiichi-Sankyo Co., Ltd.
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![Effect of AchEIs on AD patients in the 3 subgroups analyzed by 5 multidimensional rating scales. ^\#^ p \< 0.05, \* p \< 0.01, improvement versus baseline in the donepezil group; ^†^ p \< 0.01, worsening versus baseline in the galantamine group.](dee-0005-0135-g02){#F2}

![Statistical maps showing perfusion changes in the 3 treatment groups. Increased perfusion is indicated by 'hot' colors and decreased perfusion by 'cold' colors. All treatment groups showed a significant increase in rCBF mainly in the frontal lobe. A significant reduction in rCBF was observed in the temporal lobe and cingulate gyrus of all treatment groups.](dee-0005-0135-g03){#F3}

###### 

Adverse events reported in the 3 groups

                  Donepezil (n = 25)   Rivastigmine (n = 25)   Galantamine (n = 25)
  --------------- -------------------- ----------------------- ----------------------
  Nausea          3 (12.0)             2 (8.0)                 1 (4.0)
  Vomiting        2 (8.0)              1 (4.0)                 0
  Headache        1 (4.0)              1 (4.0)                 1 (4.0)
  Dizziness       0                    1 (4.0)                 1 (4.0)
  Sedation        0                    0                       2 (8.0)
  Skin problems   0                    2 (8.0)                 0
  Anorexia        1 (4.0)              0                       0
  Agitation       0                    0                       1 (4.0)

Data are presented as number (%) of patients.

###### 

Demographic features of the patients

                                   Donepezil (n = 19)   Rivastigmine (n = 17)   Galantamine (n = 19)
  -------------------------------- -------------------- ----------------------- ----------------------
  Age, years                       78.4±6.5             77.2±5.4                77.4±6.0
  Gender, men/women                9/10                 8/11                    8/9
  Length of education, years       12.3±2.4             13.2±3.0                11.0±2.5
  Duration of disease, years       3.1±0.8              2.6±0.9                 3.2±0.8
  APOE ε4 carrier, n (%)           10 (52.6)            9 (52.9)                9 (47.4)
  Duration of medication, months   12.3±2.4             12.8±1.8                11.8±2.2

APOE = Apolipoprotein E.

###### 

Results of the 5 multidimensional rating scales in the 3 treatment groups

                  Baseline     6 months                                      12 months
  --------------- ------------ --------------------------------------------- -------------------------------------------
  MMSE                                                                       
   Donepezil      21.0±3.9     22.0±3.3[^\*^](#T3F2){ref-type="table-fn"}    21.3±4.3
   Rivastigmine   21.0±3.5     22.6±3.2                                      21.1±3.6
   Galantamine    20.8±3.7     21.6±3.3                                      18.9±3.7
  ADAS-cog                                                                   
   Donepezil      18.2±8.1     16.6±5.9                                      16.5±8.0
   Rivastigmine   16.9±4.6     17.2±3.8                                      16.5±4.1
   Galantamine    15.5±5.4     16.6±6.9                                      18.6±7.2
  TMT-Part A                                                                 
   Donepezil      107.5±35.9   86.5±34.4[^\#^](#T3F1){ref-type="table-fn"}   89.9±36.8
   Rivastigmine   95.3±33.5    98.2±35.2                                     80.7±28.7
   Galantamine    88.8±37.5    100.3±42.1                                    85.6±48.3
  NPI                                                                        
   Donepezil      4.2±2.8      3.9±2.7                                       3.5±3.0
   Rivastigmine   4.3±4.5      3.6±2.8                                       4.0±3.9
   Galantamine    4.8±3.1      3.7±2.2                                       4.8±3.6
  FAQ                                                                        
   Donepezil      13.4±8.1     14.4±6.3                                      12.6±7.3
   Rivastigmine   12.9±6.2     13.6±4.5                                      13.4±4.2
   Galantamine    12.3±6.7     13.4±6.3                                      15.9±7.6[^†^](#T3F3){ref-type="table-fn"}

p \< 0.05

p \< 0.01, improvement versus baseline

p \< 0.01, worsening versus baseline.

###### 

Effects of AchEIs on ADAS-cog scores for each assessment category

  ADAS-cog category             Donepezil   Rivastigmine   Galantamine                                                           
  ----------------------------- ----------- -------------- ------------- -------------------------------------------- ---------- ----------
  Memory: 1 + 9 + 10 + 11       −4.8±7.7    −7.1±8.5       −2.1±5.3      −3.9±6.2                                     −1.1±7.1   −3.5±7.6
  Language: 2 + 3 + 4 + 5 + 6   −0.7±1.5    −0.6±1.3       −0.0±0.8      −0.1±0.9                                     0.1±1.2    0.1±1.2
  Praxis: 7 + 8                 −0.4±2.2    −0.9±2.4       −0.6±1.5      −1.6±1.6[^\*^](#T4F1){ref-type="table-fn"}   −0.8±2.2   −1.2±2.1

Values are expressed as changes from baseline (means±SD).

p \< 0.01, improvement versus baseline.

###### 

Effects of AchEIs on NPI subdomains

  NPI subdomain                     Donepezil   Rivastigmine   Galantamine                         
  --------------------------------- ----------- -------------- ------------- ---------- ---------- --------------------------------------------
  Delusions                         −0.2±0.4    −0.1±0.7       −0.4±0.9      −0.2±1.2   −0.1±0.5   0.0±0.5
  Hallucinations                    0.1±0.2     0.0±0.0        0.0±0.4       0.1±0.8    −0.1±0.3   −0.1±0.3
  Agitation/aggression              0.1±0.8     0.0±1.0        −0.4±1.1      −0.3±0.9   0.2±0.8    0.8±0.8[^\*^](#T5F2){ref-type="table-fn"}
  Depression/dysphoria              0.0±0.8     0.0±0.7        −0.1±0.5      0.1±0.6    0.1±0.8    0.2±0.6
  Anxiety                           −0.2±0.7    −0.1±0.9       0.0±1.0       −0.1±0.8   −0.1±0.5   0.1±0.7
  Euphoria                          0.1±0.3     0.1±0.3        −0.2±0.6      −0.2±0.6   0.0±0.4    0.1±0.3
  Apathy                            −0.3±1.0    0.1±1.1        0.1±1.2       0.2±0.8    −0.2±0.8   −0.3±0.7
  Disinhibition                     0.1±0.4     0.0±0.4        −0.1±0.6      −0.2±0.6   0.4±0.5    0.0±0.0
  Irritability/lability             0.1±1.0     −0.1±1.1       −0.1±0.8      0.1±0.9    0.1±0.7    0.4±0.7
  Aberrant motor behavior           −0.2±0.7    −0.4±0.8       −0.2±0.6      −0.1±0.9   −0.3±0.5   −0.4±0.5[^\#^](#T5F1){ref-type="table-fn"}
  Sleep disturbance                 0.0±0.7     0.1±0.7        −0.1±1.0      −0.1±0.8   0.0±0.4    0.4±0.7
  Appetite and eating disturbance   −0.1±0.4    −0.1±0.4       0.1±0.7       0.3±0.8    −0.1±0.7   0.0±0.8

Values are expressed as changes from baseline (means±SD).

p \< 0.05

p \< 0.01, worsening versus baseline.

###### 

Brain regions showing relative perfusion changes in the 3 treatment groups

                    Donepezil   Rivastigmine                         Galantamine                                                 
  ----------------- ----------- ------------------------------------ ------------- ------------------------------------- ------- -------------------------------------
  *rCBF increase*                                                                                                                
  Left              4.41        Medial frontal gyrus, GM (BA 11)     4.36          Cuneus                                4.01    Superior temporal gyrus, GM (BA 13)
                    4.22        Precuneus, GM (BA 31)                3.75          Precuneus, WM                         3.53    Lateral globus pallidus
                    4.15        Middle temporal gyrus, WM            3.35          Middle frontal gyrus, GM (BA 8)       3.37    Precentral gyrus, GM (BA 4)
                    3.89        Insula, WM                                                                                       
                    3.33        Middle frontal gyrus, GM (BA 9)                                                                  
                    3.20        Middle frontal gyrus, WM                                                                         
                    3.10        Postcentral gyrus, WM                                                                            
                    3.02        Middle frontal gyrus, GM (BA 10)                                                                 
                                                                                                                                 
  Right             4.05        Putamen                              5.19          Middle occipital gyrus, GM (BA 19)    3.74    Middle occipital gyrus, GM (BA 19)
                    3.84        Superior frontal gyrus, WM           3.66          Lingual gyrus, WM                     3.37    Lentiform nucleus
                    3.20        Superior frontal gyrus, GM (BA 10)   3.39          Precuneus, GM (BA 7)                          
                    3.20        Superior frontal gyrus, WM           3.32          Thalamus (medial dorsal nucleus)              
                                                                     3.24          Thalamus                                      
                                                                                                                                 
  *rCBF decrease*                                                                                                                
  Left              −3.01       Superior temporal gyrus, WM          −3.00         Cingulate gyrus, GM (BA 24)           −3.08   Sublobar, extranuclear, WM
                    −3.05       Cuneus, WM                           −3.34         Inferior semilunar lobule, GM         −3.10   Subgyral, WM
                    −4.59       Sublobar, extranuclear, WM           −3.64         Middle temporal gyrus, GM (BA 21)     −3.18   Inferior parietal lobule, WM
                    −5.43       Sublobar, extranuclear, WM           −3.76         Medial frontal gyrus, GM (BA 10)      −3.26   Caudate head
                                                                     −3.98         Subgyral, WM                          −3.38   Caudate tail
                                                                     −4.02         Cingulate gyrus, GM (BA 31)                   
                                                                     −4.06         Superior temporal gyrus, GM (BA 38)           
                                                                     −4.45         Subgyral                                      
                                                                                                                                 
  Right             −3.01       Thalamus (medial dorsal nucleus)     −3.00         Subgyral, WM                          −3.18   Middle temporal gyrus, WM
                    −3.38       Supramarginal gyrus, WM              −3.50         Inferior temporal gyrus, GM (BA 20)   −3.82   Anterior cingulate
                    −3.56       Middle temporal gyrus, GM (BA 21)    −4.00         Temporal lobe                         −3.87   Cingulate gyrus, WM
                    −3.86       Superior temporal gyrus, WM          −4.31         Anterior cingulate, GM (BA 32)                
                    −4.02       Medial frontal gyrus, GM (BA 6)      −4.73         Sublobar, extranuclear, WM                    
                    −4.80       Uncus, GM (BA 28)                                                                                

Regions with Z-score changes ≥3 are shown. GM = Gray matter; WM = white matter; BA = approximate Brodmann area.
